Your browser doesn't support javascript.
loading
Correlación de valores de TTPa con anti factor Xa para establecer rango terapéutico en tratamiento anticoagulante con heparina sódica / Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin
Mariné, Leopoldo; Sánchez, Gonzalo; Vargas, José Francisco; Zúñiga, Pamela; Aizman, Andrés; Mertens, Renato; Bergoeing, Michel; Muñoz, Blanca.
Afiliação
  • Mariné, Leopoldo; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Sánchez, Gonzalo; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Vargas, José Francisco; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Zúñiga, Pamela; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Aizman, Andrés; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Mertens, Renato; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Bergoeing, Michel; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
  • Muñoz, Blanca; Pontificia Universidad Católica de Chile. Departamento de Cirugía Vascular y Endovascular. Santiago. CL
Rev. méd. Chile ; 142(11): 1392-1397, nov. 2014. graf, tab
Article em Es | LILACS | ID: lil-734874
Biblioteca responsável: CL1.1
ABSTRACT

Background:

The therapeutic range (TR) of activated partial thromboplastin time (aPTT) for unfractionated heparin (UFH) dosing was established in the 1970 decade. Since then aPTT determination has changed. Current TR may be sub or supra-therapeutic depending on the reagents of the test, and therefore, responsible for complications of therapy.

Aim:

To establish the TR for UFH dosing in our institution using antifactor Xa analysis as reference standard. Material and

Methods:

After obtaining an informed consent, 43 blood samples were obtained for aPTT determination and antifactor Xa assay in 23 patients treated with intravenous UFH. Samples were processed at Emergency and Hemostasis Labs. We excluded patients receiving other anticoagulants, with thrombophilia, pregnancy or liver disease.

Results:

Mean aPTT values in the Hemostasis and Emergency labs ​​were 57.1 ± 18.9 and 56.6 ± 18.3 seconds, respectively (p = 0.77). The squared correlation coefficients between aPTT and antifactor Xa at hemostasis and emergency labs were R2 0.5 and 0.45 respectively, p < 0.001. Using a linear regression analysis, therapeutic aPTT range values ​​in our laboratory were established between 50 and 80 seconds, corresponding to antifactor Xa values of 0.3 to 0.7 IU/mL.

Conclusions:

According to current recommendations, validation of aPTT determination with reference techniques should be done in every institution.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: LILACS Assunto principal: Tempo de Tromboplastina Parcial / Heparina / Inibidores do Fator Xa / Anticoagulantes Idioma: Es Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: LILACS Assunto principal: Tempo de Tromboplastina Parcial / Heparina / Inibidores do Fator Xa / Anticoagulantes Idioma: Es Ano de publicação: 2014 Tipo de documento: Article